News

The Financial Express4d
Biocon Biologics partners Malaysia’s top cancer NGO for affordable cancer drugs
Biocon Biologics collaborates with Malaysia's National Cancer Society to launch a Patient Assistance Program, providing affordable biosimilars like Trastuzumab to underserved cancer patients and ...
Biocon Biologics partners with National Cancer Society of Malaysia
Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at ...
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated ...
The Lancet5d
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular ...
In the multivariate analysis, the HR for death for the FOLFOXIRI plus bevacizumab group compared with the FOLFIRI plus bevacizumab group was 0·77 (95% CI 0·61–0·96; p=0·02; appendix); ECOG performance ...